Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
18 studies found for:    brca | Open Studies | United States, Massachusetts

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
2 Recruiting Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Condition: Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
3 Recruiting The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib;   Drug: Temozolomide;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
4 Recruiting Cisplatin vs Paclitaxel for Triple Neg BRCA
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
5 Recruiting Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Conditions: Breast Cancer Metastatic;   BRCA 1 Gene Mutation;   BRCA 2 Gene Mutation
Interventions: Drug: Olaparib;   Drug: Physician's choice chemotherapy
6 Recruiting Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: Adult Solid Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier
Interventions: Drug: Veliparib;   Drug: Dinaciclib;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
7 Recruiting A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Conditions: Carcinoma of Breast;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation
Interventions: Drug: niraparib;   Drug: Physician's choice
8 Recruiting Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
Conditions: Breast Cancer;   Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: Other: counseling intervention;   Other: educational intervention;   Other: survey administration;   Behavioral: psychosocial assessment and care;   Behavioral: supportive care
9 Not yet recruiting Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.
Condition: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: Drug: OLAPARIB;   Drug: Single agent chemotherapy
10 Recruiting Eribulin in HER2 Negative Metastatic BrCa
Condition: Breast Cancer
Intervention: Drug: Eribulin
11 Recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Conditions: HER-2 Positive Breast Cancer;   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: T-DM1;   Drug: Pertuzumab;   Procedure: Excision of tumor/mastectomy
12 Recruiting A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: PM01183
13 Recruiting Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mastectomy;   Radiation: Radiation Therapy
14 Recruiting HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Condition: Breast Cancer
Interventions: Drug: HKI-272;   Procedure: Surgical Resection;   Drug: Capecitabine
15 Recruiting A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Rucaparib
16 Recruiting The Cancer of the Pancreas Screening-5 CAPS5)Study
Conditions: Pancreas Cancer;   Peutz-Jeghers Syndrome;   Gene Mutation;   Germline Mutation Carrier;   Lynch Syndrome
Intervention: Drug: Human synthetic secretin
17 Recruiting A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
18 Recruiting Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Conditions: Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel
To Top

† Indicates status has not been verified in more than two years